Navigation Links
Novozymes Reports Strong 2008 Results
Date:1/22/2009

BAGSVAERD, Denmark, January 22 /PRNewswire/ -- Leading biotechnology company Novozymes reports 13% sales growth in 2008. Earnings were also very satisfactory. Growth outlook for 2009 of 8-13% in DKK in an uncertain market. Strong long-term trends lead to new, increased targets and higher investments to support higher future growth level.

    - 2008 sales up by 13% in local currencies (LCY), 10% in DKK, ending at
    DKK 8,146m
    - Sales growth of 5% in LCY and 10% in DKK in the fourth quarter
    - Operating profit of DKK 1,504m, a 7% increase


    (Logo:http://www.newscom.com/cgi-bin/prnh/20090122/335356 )

"2008 was a strong year for Novozymes. I'm very pleased with our performance," says Steen Riisgaard, President and CEO. "Lower growth in the fourth quarter may point to a slowdown going into 2009. But further ahead there are favorable trends and opportunities for our business, so we have upped our level of ambition and increased our long-term targets."

Enzymes for fuel ethanol production were the strongest 2008 growth contributor, outperforming growth in North American fuel ethanol output.

In view of the economic environment, Novozymes considers its 2009 growth outlook satisfactory:

    - 2009 sales growth of 8-13% in DKK and 3-8% in LCY
    - Growth in operating profit of 10-15% in DKK and in net profit of 5-10%
    in DKK
    - Free cash flow of around DKK 100-300m, reduced by a high level of
    investments

Total expected investments in 2009 are DKK 1.3-1.5 billion. This includes the building of a new enzyme plant in Nebraska, USA, at a cost of USD 160-200 million in 2009-2010. Compared to the initial announcement, this roughly represents a doubling of the capacity to be built as well as investment cost, in order to ensure that future demand from the growing biofuels market can be met in the years to come.

In the light of last year's performance and the expected long-term trends, Novozymes has increased its long-term financial targets to:

    - Organic sales growth of more than 10% p.a.
    - Operating profit margin of more than 20%
    - Return on invested capital of more than 22%


    Read the full financial statement at:
   http://www.novozymes.com/en/MainStructure/Investor/Company+Announcements/

2009/Group+financial+statement+for+2008.htm (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

    Read Novozymes Annual Report 2008 at:http://www.report2008.novozymes.com/

    Contacts

    Johan Melchior
    Tel.: +45-4446-0690
    Mobile: +45-3077-0690
    jmel@novozymes.com

    Paige Donnelly
    Tel.: +1-919-494-3209
    Mobile: +1-919-218-4501
    pagd@novozymes.com



'/>"/>
SOURCE Novozymes A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novozymes Launches Enzyme to Reduce Acrylamide in Food
2. ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):